{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T15:32:33Z","timestamp":1693063953379},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Mehr als 10 Jahre nach der Zulassung der ersten direkt wirkenden antiviralen Wirkstoffe zur Behandlung der Hepatitis\u00a0C bleibt die Inzidenz der Hepatitis-C-Virus-(HCV-)Infektion ungebrochen hoch. In manchen L\u00e4ndern stecken sich mehr Menschen neu mit dem Virus an, als Patienten durch eine erfolgreiche Therapie geheilt werden. Die Entwicklung eines prophylaktischen Impfstoffes k\u00f6nnte die Transmission des Virus unterbinden und dadurch einen wesentlichen Beitrag zur Kontrolle dieser weltweit verbreiteten Infektion leisten. In diesem Artikel werden die besonderen Herausforderungen und die aktuellen Ans\u00e4tze der HCV-Impfstoffentwicklung dargestellt.<\/jats:p><jats:p>HCV ist ein hochgradig diverses und wandlungsf\u00e4higes Virus, das zumeist dem Immunsystem entkommt und chronische Infektionen etabliert. Andererseits heilt die HCV-Infektion bei bis zu einem Drittel der exponierten Individuen aus, sodass eine sch\u00fctzende Immunit\u00e4t erreichbar ist. Zahlreiche Untersuchungen zu den Determinanten einer sch\u00fctzenden Immunit\u00e4t gegen HCV zeichnen ein immer kompletteres Bild davon, welche Ziele ein Impfstoff erreichen muss. Sehr wahrscheinlich werden sowohl starke neutralisierende Antik\u00f6rper als auch wirkungsvolle zytotoxische T\u2011Zellen gebraucht, um sicher vor einer chronischen Infektion zu sch\u00fctzen. Die Schl\u00fcsselfrage ist, welche Ans\u00e4tze besonders breit wirksame Antik\u00f6rper und T\u2011Zellen heranreifen lassen. Dies wird erforderlich sein, um vor der gro\u00dfen F\u00fclle unterschiedlicher HCV-Varianten zu sch\u00fctzen. Die j\u00fcngsten Erfolge von mRNA-Impfstoffen \u00f6ffnen neue T\u00fcren auch f\u00fcr die HCV-Impfstoffforschung. Kombiniert mit einem tieferen Verst\u00e4ndnis der Struktur und Funktion der viralen H\u00fcllproteine, der Identifizierung kreuzprotektiver Antik\u00f6rper- und T\u2011Zellepitope sowie der Nutzung standardisierter Verfahren zur Quantifizierung der Wirksamkeit von Impfkandidaten ergeben sich neue Perspektiven f\u00fcr die Entwicklung eines Impfstoffes.<\/jats:p>","DOI":"10.1007\/s00103-021-03477-9","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T09:02:57Z","timestamp":1641891777000},"page":"183-191","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Entwicklungsans\u00e4tze f\u00fcr Impfstoffe gegen Hepatitis-C-Virus-Infektionen"],"prefix":"10.1007","volume":"65","author":[{"given":"Dorothea","family":"Bankwitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Krey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"3477_CR1","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact","author":"WHO","year":"2021","unstructured":"WHO (2021) Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact (Licence: CC BY-NC-SA 3.0 IGO)"},{"key":"3477_CR2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1017\/S0950268817001947","volume":"145","author":"SHI Hofstraat","year":"2017","unstructured":"Hofstraat\u00a0SHI, Falla\u00a0AM, Duffell\u00a0EF et\u00a0al (2017) Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU\/EEA: a\u00a0systematic review. Epidemiol Infect 145:2873\u20132885","journal-title":"Epidemiol Infect"},{"key":"3477_CR3","volume-title":"Zur Situation bei wichtigen Infektionskrankheiten in Deutschland \u2013 Hepatitis C im Jahr 2019","author":"R Zimmermann","year":"2020","unstructured":"Zimmermann\u00a0R, Bremer\u00a0V, Kollan\u00a0C, Krings\u00a0A, Schmidt\u00a0D, Steffen\u00a0G, Dudareva\u00a0S (2020) Zur Situation bei wichtigen Infektionskrankheiten in Deutschland \u2013 Hepatitis C im Jahr 2019 (Epid Bull 30\/31)"},{"key":"3477_CR4","volume-title":"Global hepatitis report 2017","author":"WHO","year":"2017","unstructured":"WHO (2017) Global hepatitis report 2017 (Licence: CC BY-NC-SA 3.0 IGO)"},{"key":"3477_CR5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-019-1411-9","volume":"17","author":"N Scott","year":"2019","unstructured":"Scott\u00a0N, Wilson\u00a0DP, Thompson\u00a0AJ et\u00a0al (2019) The case for a\u00a0universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Med 17:175","journal-title":"BMC Med"},{"key":"3477_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2055-6640(20)30329-0","volume":"3","author":"AM Hill","year":"2017","unstructured":"Hill\u00a0AM, Nath\u00a0S, Simmons\u00a0B (2017) The road to elimination of hepatitis C: analysis of cures versus new infections in 91\u00a0countries. J\u00a0Virus Erad 3:117\u2013123","journal-title":"J Virus Erad"},{"key":"3477_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","volume":"74","author":"S Blach","year":"2021","unstructured":"Blach\u00a0S, Kondili\u00a0LA, Aghemo\u00a0A et al (2021) Impact of COVID-19 on global HCV elimination efforts. J\u00a0Hepatol 74:31\u201336","journal-title":"J Hepatol"},{"key":"3477_CR8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fpubh.2020.00424","volume":"8","author":"I Sperle","year":"2020","unstructured":"Sperle\u00a0I, Steffen\u00a0G, Leendertz\u00a0SA et\u00a0al (2020) Prevalence of hepatitis B, C, and D in Germany: results from a\u00a0scoping review. Front Public Health 8:424","journal-title":"Front Public Health"},{"key":"3477_CR9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson\u00a0PK, Mathers\u00a0BM, Cowie\u00a0B et\u00a0al (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:571\u2013583","journal-title":"Lancet"},{"key":"3477_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","volume":"6","author":"F Jin","year":"2021","unstructured":"Jin\u00a0F, Dore\u00a0GJ, Matthews\u00a0G et al (2021) Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a\u00a0systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:39\u201356","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3477_CR11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","volume":"24","author":"M Martinello","year":"2017","unstructured":"Martinello\u00a0M, Grebely\u00a0J, Petoumenos\u00a0K et\u00a0al (2017) HCV reinfection incidence among individuals treated for recent infection. J\u00a0Viral Hepat 24:359\u2013370","journal-title":"J Viral Hepat"},{"key":"3477_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/jvh.13035","volume":"26","author":"J Schulkind","year":"2019","unstructured":"Schulkind\u00a0J, Stephens\u00a0B, Ahmad\u00a0F et al (2019) High response and re-infection rates among people who inject drugs treated for hepatitis C in a\u00a0community needle and syringe programme. J\u00a0Viral Hepat 26:519\u2013528","journal-title":"J Viral Hepat"},{"key":"3477_CR13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12916-015-0440-2","volume":"13","author":"N Scott","year":"2015","unstructured":"Scott\u00a0N, Mcbryde\u00a0E, Vickerman\u00a0P et al (2015) The role of a\u00a0hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med 13:198","journal-title":"BMC Med"},{"key":"3477_CR14","doi-asserted-by":"crossref","first-page":"e0156213","DOI":"10.1371\/journal.pone.0156213","volume":"11","author":"J Stone","year":"2016","unstructured":"Stone\u00a0J, Martin\u00a0NK, Hickman\u00a0M et al (2016) The potential impact of a\u00a0hepatitis C vaccine for people who inject drugs: is a\u00a0vaccine needed in the age of direct-acting antivirals? PLoS ONE 11:e156213","journal-title":"PLoS ONE"},{"issue":"3","key":"3477_CR15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/jcm10030551","volume":"10","author":"T Domovitz","year":"2021","unstructured":"Domovitz\u00a0T, Gal-Tanamy\u00a0M (2021) Tracking down the epigenetic footprint of HCV-induced hepatocarcinogenesis. J\u00a0Clin Med 10(3):551","journal-title":"J Clin Med"},{"key":"3477_CR16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","volume":"59","author":"DB Smith","year":"2014","unstructured":"Smith\u00a0DB, Bukh\u00a0J, Kuiken\u00a0C et\u00a0al (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318\u2013327","journal-title":"Hepatology"},{"key":"3477_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann\u00a0AU, Lam\u00a0NP, Dahari\u00a0H et al (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103\u2013107","journal-title":"Science"},{"key":"3477_CR18","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","volume":"8","author":"RM Ribeiro","year":"2012","unstructured":"Ribeiro\u00a0RM, Li\u00a0H, Wang\u00a0S et\u00a0al (2012) Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 8:e1002881","journal-title":"PLoS Pathog"},{"key":"3477_CR19","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3389\/fimmu.2018.01396","volume":"9","author":"LJ Stroh","year":"2018","unstructured":"Stroh\u00a0LJ, Nagarathinam\u00a0K, Krey\u00a0T (2018) Conformational flexibility in the CD81-binding site of the hepatitis C virus glycoprotein E2. Front Immunol 9:1396","journal-title":"Front Immunol"},{"key":"3477_CR20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature13117","volume":"509","author":"AG Khan","year":"2014","unstructured":"Khan\u00a0AG, Whidby\u00a0J, Miller\u00a0MT et\u00a0al (2014) Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509:381\u2013384","journal-title":"Nature"},{"key":"3477_CR21","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","volume":"342","author":"L Kong","year":"2013","unstructured":"Kong\u00a0L, Giang\u00a0E, Nieusma\u00a0T et\u00a0al (2013) Hepatitis C virus E2 envelope glycoprotein core structure. Science 342:1090\u20131094","journal-title":"Science"},{"key":"3477_CR22","doi-asserted-by":"crossref","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","volume":"6","author":"YP de Jong","year":"2014","unstructured":"de Jong\u00a0YP, Dorner\u00a0M, Mommersteeg\u00a0MC et\u00a0al (2014) Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med 6:254ra129","journal-title":"Sci Transl Med"},{"key":"3477_CR23","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3389\/fimmu.2018.02146","volume":"9","author":"J Prentoe","year":"2018","unstructured":"Prentoe\u00a0J, Bukh\u00a0J (2018) Hypervariable region 1 in envelope protein 2 of hepatitis C virus: a linchpin in neutralizing antibody evasion and viral entry. Front Immunol 9:2146","journal-title":"Front Immunol"},{"key":"3477_CR24","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1128\/JVI.02200-09","volume":"84","author":"D Bankwitz","year":"2010","unstructured":"Bankwitz\u00a0D, Steinmann\u00a0E, Bitzegeio\u00a0J et\u00a0al (2010) Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J\u00a0Virol 84:5751\u20135763","journal-title":"J Virol"},{"key":"3477_CR25","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.01594-10","volume":"85","author":"J Prentoe","year":"2011","unstructured":"Prentoe\u00a0J, Jensen\u00a0TB, Meuleman\u00a0P et\u00a0al (2011) Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J\u00a0Virol 85:2224\u20132234","journal-title":"J Virol"},{"key":"3477_CR26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2014-308724","volume":"65","author":"A von Delft","year":"2016","unstructured":"von Delft\u00a0A, Humphreys\u00a0IS, Brown\u00a0A et al (2016) The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut 65:112\u2013123","journal-title":"Gut"},{"key":"3477_CR27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","volume":"384","author":"K Page","year":"2021","unstructured":"Page\u00a0K, Melia\u00a0MT, Veenhuis\u00a0RT et\u00a0al (2021) Randomized trial of a\u00a0vaccine regimen to prevent chronic HCV infection. N\u00a0Engl J Med 384:541\u2013549","journal-title":"N Engl J Med"},{"key":"3477_CR28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3389\/fimmu.2018.01032","volume":"9","author":"R Burm","year":"2018","unstructured":"Burm\u00a0R, Collignon\u00a0L, Mesalam\u00a0AA, Meuleman\u00a0P (2018) Animal models to study hepatitis C virus infection. Front Immunol 9:1032","journal-title":"Front Immunol"},{"issue":"11","key":"3477_CR29","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.3390\/ijms21113869","volume":"21","author":"KA Berggren","year":"2020","unstructured":"Berggren\u00a0KA, Suzuki\u00a0S, Ploss\u00a0A (2020) Animal models used in hepatitis C virus research. Int J Mol Sci 21(11):3869. https:\/\/doi.org\/10.3390\/ijms21113869","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3477_CR30","doi-asserted-by":"crossref","first-page":"a036970","DOI":"10.1101\/cshperspect.a036970","volume":"10","author":"A Ploss","year":"2020","unstructured":"Ploss\u00a0A, Kapoor\u00a0A (2020) Animal models of hepatitis C virus infection. Cold Spring Harb Perspect Med 10(5):a36970","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3477_CR31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.29494","volume":"68","author":"S Trivedi","year":"2018","unstructured":"Trivedi\u00a0S, Murthy\u00a0S, Sharma\u00a0H et al (2018) Viral persistence, liver disease, and host response in a\u00a0hepatitis C\u2011like virus rat model. Hepatology 68:435\u2013448","journal-title":"Hepatology"},{"key":"3477_CR32","doi-asserted-by":"crossref","first-page":"e00216","DOI":"10.1128\/mBio.00216-13","volume":"4","author":"A Kapoor","year":"2013","unstructured":"Kapoor\u00a0A, Simmonds\u00a0P, Scheel\u00a0TK et\u00a0al (2013) Identification of rodent homologs of hepatitis C virus and pegiviruses. mBio 4:e216\u2013213","journal-title":"mBio"},{"key":"3477_CR33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/978-1-4939-8976-8_30","volume":"1911","author":"JR Bailey","year":"2019","unstructured":"Bailey\u00a0JR, Urbanowicz\u00a0RA, Ball\u00a0JK, Law\u00a0M, Foung\u00a0SKH (2019) Standardized method for the study of antibody neutralization of HCV pseudoparticles (HCVpp). Methods Mol Biol 1911:441\u2013450","journal-title":"Methods Mol Biol"},{"key":"3477_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321190","author":"D Bankwitz","year":"2020","unstructured":"Bankwitz\u00a0D, Bahai\u00a0A, Labuhn\u00a0M et\u00a0al (2020) Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2020-321190","journal-title":"Gut"},{"key":"3477_CR35","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMsb2109093","volume":"385","author":"TJ Liang","year":"2021","unstructured":"Liang\u00a0TJ, Feld\u00a0JJ, Cox\u00a0AL, Rice\u00a0CM (2021) Controlled human infection model\u2014fast track to HCV vaccine? N\u00a0Engl J Med 385:1235\u20131240","journal-title":"N Engl J Med"},{"key":"3477_CR36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"T Ura","year":"2014","unstructured":"Ura\u00a0T, Okuda\u00a0K, Shimada\u00a0M (2014) Developments in viral vector-based vaccines. Vaccines (Basel) 2:624\u2013641","journal-title":"Vaccines (Basel)"},{"key":"3477_CR37","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"Barnes\u00a0E, Folgori\u00a0A, Capone\u00a0S et al (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra1","journal-title":"Sci Transl Med"},{"key":"3477_CR38","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones\u00a0SM, Feldmann\u00a0H, Stroher\u00a0U et\u00a0al (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786\u2013790","journal-title":"Nat Med"},{"key":"3477_CR39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","volume":"28","author":"JB Case","year":"2020","unstructured":"Case\u00a0JB, Rothlauf\u00a0PW, Chen\u00a0RE et al (2020) Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-coV-2-mediated pathogenesis in mice. Cell Host Microbe 28:465\u2013474.e4","journal-title":"Cell Host Microbe"},{"key":"3477_CR40","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.4049\/jimmunol.177.10.7462","volume":"177","author":"S Capone","year":"2006","unstructured":"Capone\u00a0S, Zampaglione\u00a0I, Vitelli\u00a0A et\u00a0al (2006) Modulation of the immune response induced by gene electrotransfer of a\u00a0hepatitis C virus DNA vaccine in nonhuman primates. J\u00a0Immunol 177:7462\u20137471","journal-title":"J Immunol"},{"key":"3477_CR41","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","volume":"6","author":"L Swadling","year":"2014","unstructured":"Swadling\u00a0L, Capone\u00a0S, Antrobus\u00a0RD et al (2014) A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6:261ra153","journal-title":"Sci Transl Med"},{"key":"3477_CR42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrmicro2668","volume":"9","author":"SA Plotkin","year":"2011","unstructured":"Plotkin\u00a0SA, Plotkin\u00a0SL (2011) The development of vaccines: how the past led to the future. Nat Rev Microbiol 9:889\u2013893","journal-title":"Nat Rev Microbiol"},{"key":"3477_CR43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2013.05.007","volume":"145","author":"D Akazawa","year":"2013","unstructured":"Akazawa\u00a0D, Moriyama\u00a0M, Yokokawa\u00a0H et al (2013) Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 145:447\u2013455.e1\u20114","journal-title":"Gastroenterology"},{"key":"3477_CR44","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrgastro.2013.136","volume":"10","author":"JM Gottwein","year":"2013","unstructured":"Gottwein\u00a0JM, Bukh\u00a0J (2013) Viral hepatitis: cell-culture-derived HCV\u2014a promising vaccine antigen. Nat Rev Gastroenterol Hepatol 10:508\u2013509","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3477_CR45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2016-312208","volume":"67","author":"H Yokokawa","year":"2018","unstructured":"Yokokawa\u00a0H, Higashino\u00a0A, Suzuki\u00a0S et al (2018) Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a\u00a0non-human primate model. Gut 67:372\u2013379","journal-title":"Gut"},{"key":"3477_CR46","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1586\/erv.11.111","volume":"10","author":"MW Wolf","year":"2011","unstructured":"Wolf\u00a0MW, Reichl\u00a0U (2011) Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 10:1451\u20131475","journal-title":"Expert Rev Vaccines"},{"key":"3477_CR47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/bit.25545","volume":"112","author":"P Nestola","year":"2015","unstructured":"Nestola\u00a0P, Peixoto\u00a0C, Silva\u00a0RR, Alves\u00a0PM, Mota\u00a0JP, Carrondo\u00a0MJ (2015) Improved virus purification processes for vaccines and gene therapy. Biotechnol Bioeng 112:843\u2013857","journal-title":"Biotechnol Bioeng"},{"key":"3477_CR48","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","volume":"11","author":"SA Plotkin","year":"2005","unstructured":"Plotkin\u00a0SA (2005) Vaccines: past, present and future. Nat Med 11:S5\u201311","journal-title":"Nat Med"},{"key":"3477_CR49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.02.013","volume":"105","author":"JK Ball","year":"2014","unstructured":"Ball\u00a0JK, Tarr\u00a0AW, Mckeating\u00a0JA (2014) The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 105:100\u2013111","journal-title":"Antiviral Res"},{"key":"3477_CR50","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1128\/JVI.01180-10","volume":"84","author":"G Vieyres","year":"2010","unstructured":"Vieyres\u00a0G, Thomas\u00a0X, Descamps\u00a0V, Duverlie\u00a0G, Patel\u00a0AH, Dubuisson\u00a0J (2010) Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J\u00a0Virol 84:10159\u201310168","journal-title":"J Virol"},{"key":"3477_CR51","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","volume":"91","author":"QL Choo","year":"1994","unstructured":"Choo\u00a0QL, Kuo\u00a0G, Ralston\u00a0R et\u00a0al (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S\u00a0A 91:1294\u20131298","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3477_CR52","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","volume":"28","author":"SE Frey","year":"2010","unstructured":"Frey\u00a0SE, Houghton\u00a0M, Coates\u00a0S et\u00a0al (2010) Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28:6367\u20136373","journal-title":"Vaccine"},{"key":"3477_CR53","doi-asserted-by":"crossref","first-page":"e59776","DOI":"10.1371\/journal.pone.0059776","volume":"8","author":"JL Law","year":"2013","unstructured":"Law\u00a0JL, Chen\u00a0C, Wong\u00a0J et al (2013) A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a\u00a0single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 8:e59776","journal-title":"PLoS One"},{"key":"3477_CR54","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","volume":"202","author":"R Ray","year":"2010","unstructured":"Ray\u00a0R, Meyer\u00a0K, Banerjee\u00a0A et\u00a0al (2010) Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J\u00a0Infect Dis 202:862\u2013866","journal-title":"J Infect Dis"},{"key":"3477_CR55","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3389\/fmicb.2017.02163","volume":"8","author":"J Torresi","year":"2017","unstructured":"Torresi\u00a0J (2017) The rationale for a preventative HCV virus-like particle (VLP) vaccine. Front Microbiol 8:2163","journal-title":"Front Microbiol"},{"key":"3477_CR56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann\u00a0MF, Jennings\u00a0GT (2010) Vaccine delivery: a\u00a0matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787\u2013796","journal-title":"Nat Rev Immunol"},{"key":"3477_CR57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","volume":"14","author":"J Lopez-Sagaseta","year":"2016","unstructured":"Lopez-Sagaseta\u00a0J, Malito\u00a0E, Rappuoli\u00a0R, Bottomley\u00a0MJ (2016) Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J 14:58\u201368","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"3477_CR58","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1128\/JVI.72.5.3827-3836.1998","volume":"72","author":"TF Baumert","year":"1998","unstructured":"Baumert\u00a0TF, Ito\u00a0S, Wong\u00a0DT, Liang\u00a0TJ (1998) Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J\u00a0Virol 72:3827\u20133836","journal-title":"J Virol"},{"key":"3477_CR59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/jhep.2001.26523","volume":"34","author":"M Lechmann","year":"2001","unstructured":"Lechmann\u00a0M, Murata\u00a0K, Satoi\u00a0J, Vergalla\u00a0J, Baumert\u00a0TF, Liang\u00a0TJ (2001) Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34:417\u2013423","journal-title":"Hepatology"},{"key":"3477_CR60","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1128\/JVI.78.13.6995-7003.2004","volume":"78","author":"SH Jeong","year":"2004","unstructured":"Jeong\u00a0SH, Qiao\u00a0M, Nascimbeni\u00a0M et al (2004) Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J\u00a0Virol 78:6995\u20137003","journal-title":"J Virol"},{"key":"3477_CR61","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","volume":"104","author":"GA Elmowalid","year":"2007","unstructured":"Elmowalid\u00a0GA, Qiao\u00a0M, Jeong\u00a0SH et al (2007) Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci Usa 104:8427\u20138432","journal-title":"Proc Natl Acad Sci Usa"},{"key":"3477_CR62","doi-asserted-by":"crossref","first-page":"e47492","DOI":"10.1371\/journal.pone.0047492","volume":"7","author":"BY Chua","year":"2012","unstructured":"Chua\u00a0BY, Johnson\u00a0D, Tan\u00a0A et al (2012) Hepatitis C VLPs delivered to dendritic cells by a\u00a0TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 7:e47492","journal-title":"PLoS One"},{"key":"3477_CR63","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1038\/s41598-018-24762-9","volume":"8","author":"D Christiansen","year":"2018","unstructured":"Christiansen\u00a0D, Earnest-Silveira\u00a0L, Chua\u00a0B et al (2018) Immunological responses following administration of a\u00a0genotype 1a\/1b\/2\/3a quadrivalent HCV VLP vaccine. Sci Rep 8:6483","journal-title":"Sci Rep"},{"key":"3477_CR64","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1099\/jgv.0.000493","volume":"97","author":"L Earnest-Silveira","year":"2016","unstructured":"Earnest-Silveira\u00a0L, Chua\u00a0B, Chin\u00a0R et al (2016) Characterization of a\u00a0hepatitis C virus-like particle vaccine produced in a\u00a0human hepatocyte-derived cell line. J\u00a0Gen Virol 97:1865\u20131876","journal-title":"J Gen Virol"},{"key":"3477_CR65","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.1038\/s41598-019-45461-z","volume":"9","author":"D Christiansen","year":"2019","unstructured":"Christiansen\u00a0D, Earnest-Silveira\u00a0L, Grubor-Bauk\u00a0B et al (2019) Pre-clinical evaluation of a\u00a0quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep 9:9251","journal-title":"Sci Rep"},{"key":"3477_CR66","first-page":"1304","volume":"221","author":"Y Yan","year":"2020","unstructured":"Yan\u00a0Y, Wang\u00a0X, Lou\u00a0P et al (2020) A nanoparticle-based hepatitis C virus vaccine with enhanced potency. J\u00a0Infect Dis 221:1304\u20131314","journal-title":"J Infect Dis"},{"key":"3477_CR67","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.26132","volume":"57","author":"E Beaumont","year":"2013","unstructured":"Beaumont\u00a0E, Patient\u00a0R, Hourioux\u00a0C, Dimier-Poisson\u00a0I, Roingeard\u00a0P (2013) Chimeric hepatitis B virus\/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a\u00a0potential bivalent prophylactic vaccine. Hepatology 57:1303\u20131313","journal-title":"Hepatology"},{"key":"3477_CR68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","volume":"507","author":"BE Correia","year":"2014","unstructured":"Correia\u00a0BE, Bates\u00a0JT, Loomis\u00a0RJ et al (2014) Proof of principle for epitope-focused vaccine design. Nature 507:201\u2013206","journal-title":"Nature"},{"key":"3477_CR69","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine\u00a0HM, Boyington\u00a0JC, Mctamney\u00a0PM et al (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21:1065\u20131070","journal-title":"Nat Med"},{"key":"3477_CR70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","volume":"24","author":"K Xu","year":"2018","unstructured":"Xu\u00a0K, Acharya\u00a0P, Kong\u00a0R et al (2018) Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV\u20111. Nat Med 24:857\u2013867","journal-title":"Nat Med"},{"key":"3477_CR71","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.1038\/srep12501","volume":"5","author":"L He","year":"2015","unstructured":"He\u00a0L, Cheng\u00a0Y, Kong\u00a0L et al (2015) Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep 5:12501","journal-title":"Sci Rep"},{"issue":"20","key":"3477_CR72","doi-asserted-by":"publisher","first-page":"e01032-17","DOI":"10.1128\/JVI.01032-17","volume":"91","author":"BG Pierce","year":"2017","unstructured":"Pierce\u00a0BG, Boucher\u00a0EN, Piepenbrink\u00a0KH et al (2017) Structure-based design of hepatitis C virus vaccines that elicit neutralizing antibody responses to a\u00a0conserved epitope. J\u00a0Virol 91(20):e01032-17. https:\/\/doi.org\/10.1128\/JVI.01032-17","journal-title":"J Virol"},{"key":"3477_CR73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-020-00269-1","volume":"6","author":"VM Cowton","year":"2021","unstructured":"Cowton\u00a0VM, Owsianka\u00a0AM, Fadda\u00a0V et\u00a0al (2021) Development of a\u00a0structural epitope mimic: an idiotypic approach to HCV vaccine design. NPJ Vaccines 6:7","journal-title":"NPJ Vaccines"},{"issue":"6492","key":"3477_CR74","doi-asserted-by":"publisher","first-page":"eaay5051","DOI":"10.1126\/science.aay5051","volume":"368","author":"F Sesterhenn","year":"2020","unstructured":"Sesterhenn\u00a0F, Yang\u00a0C, Bonet\u00a0J et al (2020) De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science 368(6492):eaay5051. https:\/\/doi.org\/10.1126\/science.aay5051","journal-title":"Science"},{"key":"3477_CR75","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2019.11.011","volume":"72","author":"NA Brasher","year":"2020","unstructured":"Brasher\u00a0NA, Eltahla\u00a0AA, Underwood\u00a0A et\u00a0al (2020) B cell immunodominance in primary hepatitis C virus infection. J\u00a0Hepatol 72:670\u2013679","journal-title":"J Hepatol"},{"key":"3477_CR76","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","volume":"104","author":"JM Pestka","year":"2007","unstructured":"Pestka\u00a0JM, Zeisel\u00a0MB, Blaser\u00a0E et al (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a\u00a0single-source outbreak of hepatitis C. Proc Natl Acad Sci U S\u00a0A 104:6025\u20136030","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3477_CR77","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2020.09.022","volume":"74","author":"R Thimme","year":"2021","unstructured":"Thimme\u00a0R (2021) T cell immunity to hepatitis C virus: lessons for a\u00a0prophylactic vaccine. J\u00a0Hepatol 74:220\u2013229","journal-title":"J Hepatol"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-021-03477-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:04:32Z","timestamp":1643871872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-021-03477-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3477"],"URL":"https:\/\/doi.org\/10.1007\/s00103-021-03477-9","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Krey gibt an, dass kein Interessenkonflikt besteht. T.\u00a0Pietschmann und D.\u00a0Bankwitz erhalten von der ethris GmbH Studienunterst\u00fctzung. Diese Unterst\u00fctzung hat keine Relevanz f\u00fcr die inhaltlichen Aussagen der hier vorliegenden Arbeit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Die Arbeiten in den Laboren der Autoren:in werden durch die Deutsche Forschungsgemeinschaft im Kontext der Deutschen Exzellenzstrategie gef\u00f6rdert (EXC 2155 \u201eRESIST\u201c\u00a0\u2013 Project ID 39087428). T. Pietschmann wird durch F\u00f6rdermittel des Deutschen Zentrums f\u00fcr Infektionsforschung im Rahmen des HCV Vakzine Projektes unterst\u00fctzt (TTU 05.817 and TTU 05.821). Die F\u00f6rderer haben  keinen Einfluss auf den Inhalt dieses Artikels.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}